Thomas Sandgaard

Chairman of the Board, President and Chief Executive Officer

Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications, data communications and medical equipment industries. Mr. Sandgaard has a degree in electronics engineering from Denmark’s Odense University of Engineering and an MBA from Copenhagen Business School. Mr. Sandgaard has an in-depth knowledge of the industry and is the driving force of the Company strategies.

Dan Moorhead

Chief Financial Officer

Dan Moorhead is the Chief Financial Officer and responsible for all finance and accounting functions. Prior to joining Zynex, Mr. Moorhead was Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until June 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.

Robert Bird

VP of Marketing

Robert Bird is the VP of Marketing responsible for all marketing, in-side sales and compounding products within the rehabilitation and pain management markets for the Zynex Medical division of Zynex. Mr. Bird has over 20 years of sales and management experience and holds a B.S. Degree in Business Administration from California State University, Hayward.

Michael Frabotta

VP of Sales

Michael Frabotta the VP of sales and is responsible for Zynex Medical’s sales organization promoting electrotherapy and compound pharmacy products throughout the United States. Mr. Frabotta has over 14 years of successful sales and management experience with RS Medical and ERMI, Inc. At RS Medical a once national competitor in the electrotherapy arena he successfully served as a Director of Sales, National Director of Payor Contracting, Regional Manager, and Sales Representative. Mr. Frabotta received a Bachelor of Science in Nursing from the University of Pittsburgh where he specialized in Orthopaedics.

Board of Directors

Michael Cress

Michael Cress serves as Chairman & Managing Partner of MD Cress Ventures, a national firm that owns, operates and advises companies within the healthcare sector. Michael also serves as Chairman of Rainier Healthcare. Prior to MD Cress Ventures he served as the President and CEO of the Cornerstone Healthcare Group which owns and manages hospitals throughout the country. Mr. Cress also served as Vice President of Business Development for Kindred Healthcare, a publicly traded healthcare company that owns and operates hospitals, nursing homes, rehabilitation, pharmacy and other segments of the healthcare continuum. He served as the CEO of Vencor Hospital of San Diego and was also an Adjunct Professor for the Masters of Healthcare Administration program at the University of Kansas. Mr. Cress serves on several not-for-profit boards to include Rachel’s Challenge and co-founded and serves on the board for The Neighborhood. He serves on the boards or advisory boards of several companies to include Linley Capital, BankSNB, Rainier Hospice and Sleep Research.

Barry Michaels

Barry Michaels has 40 years of financial and general management experience in the medical device and biotechnology industries with industry leaders including Medtronic, Johnson and Johnson, and Baxter Healthcare, as well as having served as President or Chief Financial Officer of seven emerging stage companies. Most recently he served as a consultant to Organovo Holdings, Inc. after retiring therefrom in 2016, where he served as its Chief Financial Officer since 2011. Mr. Michaels received an MBA with a concentration in finance from San Diego State University and is a graduate of the Executive Program at the UCLA Anderson Graduate School of Management.

Josh Disbrow

Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. (“Aytu” NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology. Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals (“Ampio”, a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary “Luoxis”). Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals (“Arbor”).

Mr. Disbrow began as Arbor’s second employee and oversaw the commercialization of the company’s first product, scaling the commercial organization to over 150 people across sales, marketing, payer markets, distribution, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of $127 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (a NASDAQ traded company), a cardiovascular in vitro diagnostic company. Mr. Disbrow also served in sales management at Cyberonics (Now LivaNova plc, a NASDAQ traded company), a medical device company commercializing implantable neuromodulation devices. He started his career at Glaxo Wellcome (now GlaxoSmithKline plc), holding positions in both sales and marketing. He has a Master of Business Administration from Wake Forest University and Bachelor of Science in Management from North Carolina State University.